$MEDIF News

Last published 5d ago

5d agoMEDIFMediPharm Labs Sets Date to Report Third Quarter 2026 Financial ResultsGlobeNewswireTORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in
6d agoMEDIFMediPharm Labs Achieves Critical European Regulatory Milestone Supporting Commercialization of Proprietary Metered-Dose Cannabis Inhaler PlatformGlobeNewswireTORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in
1w agoMEDIFMediPharm Labs Appoints Greg Hunter as Chief Executive Officer and DirectorGlobeNewswireTORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in
4w agoMEDIFMediPharm Labs Expands Its International Medical Cannabis Footprint with First CBD Metered-Dose Inhaler Shipment to PanamaGlobeNewswireTORONTO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in
3mo agoMEDIFMediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDAGlobeNewswireQ2 2026 Adjusted EBITDA1 of $0.9M, the Company’s strongest quarterly performance since 20192Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025OPEX decreased 44% in Q2 2026 versus Q2 2025Net
3mo agoMEDIFMediPharm Labs Sets Date to Report Second Quarter 2026 Financial ResultsGlobeNewswireTORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in
4mo agoMEDIFMediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and DementiaGlobeNewswireResults presented by the LiBBY study team at the Alzheimer’s Association International Conference ("AAIC") demonstrated statistically significant improvements in agitation symptoms compared with placebo.The
4mo agoMEDIFMediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of ShareholdersGlobeNewswireTORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based
5mo agoMEDIFMediPharm Labs Reminds Shareholders of Upcoming Annual and Special MeetingGlobeNewswireAnnual and Special Meeting to be held virtually on Wednesday, June 17, 2026 at 11:00 a.m. (Eastern Time).The Board of Directors recommends shareholders vote FOR all director nominees and resolutions, before the 11:00
6mo agoMEDIFMediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDAGlobeNewswireQ1 2026 Positive Adjusted EBITDA(1)Net Revenue of $9M with strong gross margins of 37%OPEX decreased 28% in Q1 2026 versus Q4 2025Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright
6mo agoMEDIFMediPharm Labs Sets Date to Report First Quarter 2026 Financial ResultsGlobeNewswireTORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in
6mo agoMEDIFMediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis ReschedulingGlobeNewswireOn April 22, 2026, the U.S. Department of Justice and Drug Enforcement Administration's final order rescheduling FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I to Schedule III of
7mo agoMEDIFMediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical RevenueGlobeNewswireFY 2025 revenue of $45.1 million, an increase of 8% over 2024International Medical Cannabis revenue increased 43% year-over-year and represented more than 50% of total revenueIncreased cash balance of $10.8 Million at
7mo agoMEDIFMediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial ResultsGlobeNewswireTORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in
9mo agoMEDIFMediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEOGlobeNewswireTORONTO, Jan. 19, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids,
10mo agoMEDIFMediPharm Labs to Enter New Market with Costa Rica Supply AgreementGlobeNewswireTORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based
10mo agoMEDIFHistoric U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply ExperienceGlobeNewswireTORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in
11mo agoMEDIFMediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby ReturnsGlobeNewswireTORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced
11mo agoMEDIFMediPharm Labs Completes First Shipment to FranceGlobeNewswireTORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in
12mo agoMEDIFMediPharm Announces Complete Dismissal of Defamation Action Initiated by Apollo, Nobul and Regan McGee Under Ontario Anti-SLAPP LawGlobeNewswireTORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced
12mo agoMEDIFMediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis GainsGlobeNewswireQ3 2025 Revenue of $11.4 Million, an Increase of 17% over Q3 202483% Growth in Year-Over-Year Revenue for International Medical CannabisInternational Medical sales now 56% of Total RevenueIncreased Cash Balance of $10.6
1y agoMEDIFMediPharm Labs Sets Date to Report Third Quarter 2025 Financial ResultsGlobeNewswireTORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in
1y agoMEDIFMediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical CannabisGlobeNewswireQ2 Revenue of $11.8 Million, an Increase of 14% over Q2 202450% Growth in Revenue for International Medical CannabisInternational Medical sales now 57% of Total RevenueCash Balance of $10.4 Million at the end of Q2,
1y agoMEDIFMediPharm Labs Sets Date to Report Second Quarter 2025 Financial ResultsGlobeNewswireTORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in
1y agoMEDIFMediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime InhalerGlobeNewswireTORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in
1y agoMEDIFMediPharm Announces Voting Results from the 2025 Annual and Special Meeting of ShareholdersGlobeNewswireTORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced
1y agoMEDIFMediPharm Cautions Shareholders To Await Final Results of Annual and Special MeetingGlobeNewswireTORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, wishes to
1y agoMEDIFApollo Capital Wins Proxy Contest at MediPharm LabsGlobeNewswireMediPharm Labs' Board's Material and Unprecedented Breaches of Securities Laws Are Part of Their Undoing Apollo Capital's Entire Slate of Board Nominees Constitute the New Board of Directors for MediPharm Labs Effective
1y agoMEDIFLeading Independent Proxy Advisor Glass Lewis Recommends Shareholders Vote the GREEN proxy FOR ALL MediPharm Director NomineesGlobeNewswireTORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced
1y agoMEDIFMediPharm Reminds Shareholders to Vote in Advance of June 13 DeadlineGlobeNewswireTORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm," the "Company," "we" or "us"), a pharmaceutical company specialized in precision-based cannabinoids,
1y agoMEDIFMediPharm Announces Complete Dismissal of Dissident Court Proceeding Related to Annual and Special MeetingGlobeNewswireTORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced
1y agoMEDIFApollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World's Leading International Medical Cannabis CompanyGlobeNewswireTORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporation ("Apollo Capital"), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs
1y agoMEDIF ROMJFMediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee FacilityGlobeNewswireTORONTO, June 05, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm"), a pharmaceutical company specialized in precision-based cannabinoids, announced the closing of
1y agoMEDIFLeading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo's Arguments and Director SlateGlobeNewswireTORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced
1y agoMEDIFMediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo CapitalGlobeNewswireDemands Management's Board Nominees John Medland and Emily Jameson Withdraw Immediately or Face Public Complicity in Ongoing Alleged Systemic Violations of Securities Laws URGES SHAREHOLDERS TO VOTE THE GOLD PROXY CARD
1y agoMEDIFMediPharm Labs Responds to Fabricated Allegations from Dissident ShareholderGlobeNewswireTORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE:MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today confirmed
1y agoMEDIFAlleged Securities Fraud at MediPharm Labs Says Apollo CapitalGlobeNewswireMultiple Highly Credible Sources Reveal Disturbing Evidence of Alleged Systemic Violations of Securities Laws at MediPharm Labs; Immediate Regulatory Action Demanded Apollo Capital's Six Director Nominees Are Committed
1y agoMEDIFApollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck's Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue PharmaGlobeNewswireOpioid-Pusher Pidduck, Chairman Chris Taves and the Current MediPharm Board Have Presided Over $1 Billion in Shareholder Value Destruction while funneling $5,587,059 of the Shareholders' Money Directly into Pidduck's
1y agoMEDIFMediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution AgreementGlobeNewswireTORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in
1y agoMEDIFApollo Capital Comments on MediPharm Labs' Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual MeetingGlobeNewswireMediPharm Labs Board Continues to Obstruct the Appointment and Oversight of an Independent Chair Failure to Appoint an Independent Chair to Oversee the Election of Directors at the Annual Meeting Prevents Shareholders
1y agoMEDIFApollo Capital Issues a With Prejudice Offer to MediPharm Labs and Its Board of Directors to Ensure Shareholder Rights Are Protected at the 2025 Annual MeetingGlobeNewswireBelieves the Board Continues to Take Oppressive Actions Which Fundamentally Disregard the Rights and Interests of Shareholders Asserts the Board's Unlawful, Desperate and Self-Serving Tactics Clearly Indicate That the
3y agoMEDIFMediPharm Labs Settles an Outstanding Claim for $9MPR NewswireTORONTO, Oct. 2, 2023 /CNW/ - MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a company specialized in precision-based cannabinoids, is
3y agoMEDIFMediPharm Labs Launches new GMP Products to the Australian Medical Cannabis MarketPR NewswireThe launch includes GMP strain-specific full spectrum cannabis oil and inhalation cartridge products to be distributed to patients under the MediPharm Labs Beacon Medical brand. As of July 2023, all Australian medical
3y agoMEDIFMediPharm Labs Improves Domestic Sales Gross Margin with Termination of Shelter Cannabis Brands Royalty AgreementPR NewswireMediPharm Labs and Shelter Cannabis Brands have terminated their royalty agreement with a one-time cash payment.Agreement includes the elimination of ongoing royalty payments, for a one-time lump sum payment.TORONTO,
3y agoMEDIFMediPharm Labs Completes Sale of Vacant Land for Cash Proceeds of $1.9 millionPR NewswireMediPharm Labs sold vacant land in Napanee, Ontario last utilized in 2021 for outdoor cannabis growing activities. The land was acquired by MediPharm as part of the VIVO Cannabis acquisition in April 2023.The net cash
3y agoMEDIFMediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia PatientsPR NewswireMediPharm Labs wholly owned subsidiary Harvest Medicine has published a study in the peer-reviewed American Journal of Endocannabinoid Medicine.This is the largest peer reviewed published study of its kind
3y agoMEDIFMediPharm Labs Reports Second Quarter Results with Doubling of Revenue and Record Margin GrowthPR NewswireTORONTO, Aug. 14, 2023 /CNW/ - MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based
3y agoMEDIFMediPharm Labs Sets Date to Report Second Quarter 2023 Financial ResultsPR NewswireTORONTO, Aug. 10, 2023 /PRNewswire/ - MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in
3y agoMEDIFMediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner StudyPR NewswireMediPharm Labs shares progress on clinical trials, including the provision of clinical trial materials and research support to multiple partners.Research support consists of both product and services for partner studies
3y agoMEDIFMediPharm Labs Receives Award for CBD Brand of the YearPR NewswireFor the second year MediPharm Labs' pharma-quality CBD dominant oil line has been awarded the CBD Brand of the year by KIND Magazine.MediPharm Labs was also awarded the CBN Product of the Year and the Kindest Health